Nature Communications (Jan 2022)
Clenbuterol exerts antidiabetic activity through metabolic reprogramming of skeletal muscle cells
- Jaroslawna Meister,
- Derek B. J. Bone,
- Jonas R. Knudsen,
- Luiz F. Barella,
- Thomas J. Velenosi,
- Dmitry Akhmedov,
- Regina J. Lee,
- Amanda H. Cohen,
- Oksana Gavrilova,
- Yinghong Cui,
- Gerard Karsenty,
- Min Chen,
- Lee S. Weinstein,
- Maximilian Kleinert,
- Rebecca Berdeaux,
- Thomas E. Jensen,
- Erik A. Richter,
- Jürgen Wess
Affiliations
- Jaroslawna Meister
- Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases
- Derek B. J. Bone
- Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases
- Jonas R. Knudsen
- Departments of Nutrition, Exercise and Sports, University of Copenhagen
- Luiz F. Barella
- Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases
- Thomas J. Velenosi
- Faculty of Pharmaceutical Sciences, University of British Columbia
- Dmitry Akhmedov
- Departments of Integrative Biology and Pharmacology, Houston Medical School
- Regina J. Lee
- Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases
- Amanda H. Cohen
- Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases
- Oksana Gavrilova
- Mouse Metabolism Core, National Institute of Diabetes and Digestive and Kidney Diseases
- Yinghong Cui
- Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases
- Gerard Karsenty
- Departments of Genetics and Development, Vagelos College of Physicians and Surgeons, Columbia University
- Min Chen
- Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases
- Lee S. Weinstein
- Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases
- Maximilian Kleinert
- Departments of Nutrition, Exercise and Sports, University of Copenhagen
- Rebecca Berdeaux
- Departments of Integrative Biology and Pharmacology, Houston Medical School
- Thomas E. Jensen
- Departments of Nutrition, Exercise and Sports, University of Copenhagen
- Erik A. Richter
- Departments of Nutrition, Exercise and Sports, University of Copenhagen
- Jürgen Wess
- Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases
- DOI
- https://doi.org/10.1038/s41467-021-27540-w
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 14
Abstract
In this study, the authors demonstrated that agents targeting skeletal muscle metabolism by modulating β2-adrenergic receptor-dependent signaling may prove beneficial as novel antidiabetic drugs.
